News

Zacks Investment Research on MSN1h
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer
AbbVie ABBV announced that the FDA has granted accelerated approval to its antibody-drug conjugate (ADC), telisotuzumab ...
PMLive3h
Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis
Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...
Merck Gets FDA Approval for Tumor Treatment Welireg
Merck has received approval from the Food and Drug Administration for Welireg, its oral inhibitor for patients with certain rare types of neuroendocrine tumors. The company said Wednesday the ...
MedPage Today17h
FDA OKs New Drug for Lung Cancer With c-Met Overexpression
The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, ...
BioWorld17h
US FDA clears Abbvie’s c-Met lung cancer ADC
The U.S. FDA granted Abbvie Inc. accelerated approval for antibody-drug conjugate (ADC) Teliso-V (telisotuzumab vedotin), newly branded Emrelis, making it the first treatment for previously treated ...
Fierce Pharma18h
AbbVie advances solid tumor agenda with FDA nod for lung cancer ADC Emrelis
After flexing its antibody-drug conjugate bona fides at last year’s American Society of Clinical Oncology (ASCO) conference, ...
FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases
FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes ...
US FDA approves AbbVie's drug for a type of lung cancer
The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...
CURE19h
FDA Approves Emrelis in Previously Treated, Advanced NSCLC
The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met ...
The American Journal of Managed Care19h
Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung ...
US FDA expands use of Merck's cancer drug for adrenal gland tumors
The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two ...
Pharmaceutical Technology on MSN1d
GSK to spend $2bn on Phase III liver disease drug acquisition
Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...